Cambrex Corp., a manufacturer of small molecule active pharmaceutical ingredients (APIs), and finished dosage forms, is investing $1 million at its High Point, NC site to add 1,300 sq.-ft. of analytical lab space and nine chemical research and development scientists, as well as six analytical research and development scientists. This investment follows the new $3.2 million, 11,000 sq.-ft. analytical lab, completed in April 2018.
 
The expansion will include the installation of an additional 10 ultra-performance liquid chromatography (UPLC) instruments, and is set to be completed by the end of 2018.
 
“Cambrex is seeing a significant increase in new projects, resulting in increased demand for analytical development capabilities within the Cambrex organization,” said Brian Swierenga, vice president, Operations and Site Director for Cambrex High Point. “This further expansion will not only increase Cambrex’s internal analytical capabilities and capacity, but will assist in getting new products to commercial launch faster.”
 
At the facility, Cambrex produces complex APIs and intermediates requiring multi-step synthetic processes in batch sizes from milligrams to 100kg to support clinical trials from Phase I to Phase III. The site is licensed with the US Drug Enforcement Administration (DEA) to manufacture Schedule II to Schedule V controlled substances.
 
The company has invested more than $9 million at the site since its acquisition of PhamaCore in 2016.